MicrobiologyPLoS PathogensPeer-reviewed
Topical Formulation of Repurposed FDA-Approved Compounds Inhibits Pseudomonas aeruginosa ExoU and Improves Corneal Infection Outcomes
Daniel M. Foulkes, David Garth Fernig, Keri McLean…·Stephen B. Kaye
This study identifies FDA-approved compounds that inhibit ExoU, a virulence factor in Pseudomonas aeruginosa, and shows their efficacy in reducing corneal infection severity in multiple models.